高危子宫内膜癌术后辅助联合放化疗的研究  

Combined Chemotherapy and Radiotherapy as Adjuvant Treatment for High-risk Endometrial Cancer

作　　者：苗劲蔚[1] 夏宁[1] 徐春玉[1] 段微[1] 吴玉梅[1] 郝霞[1] 

机构地区：[1]首都医科大学附属北京妇产医院妇瘤科,北京100006

出　　处：《医学综述》2012年第18期3140-3143,共4页Medical Recapitulate

基　　金：首都医学发展基金(2007-1049)

摘　　要：目的分析高危子宫内膜癌术后单纯放疗与联合放化疗的疗效及毒性作用。方法回顾性分析1999～2007年接受病理分期性手术及术后辅助治疗的172例高危子宫内膜癌患者的临床资料。结果 172例患者3年和5年的疾病特异性生存(DSS)率分别为87.09%和78.17%。联合放化疗与单纯放疗的DSS率和复发率比较差异有统计学意义(P=0.020、0.004)。化疗后放疗与单纯放疗的毒性作用比较差异无统计学意义(P=0.638)。结论高危子宫内膜癌联合放化疗可明显提高DSS率,减少复发率。联合方式中,化疗后放疗更为安全,可行性大。Objective To investigate the feasibility,safety and toxicity of combined chemotherapy and radiotherapy as the adjuvant treatment following staging surgery for high-risk endometrial cancer.Methods The records of 172 patients with high—risk endometrial cancer,who underwent endometrial cancer staging surgery and postoperative treatments in our department between 1999 to 2007 were reviewed.Results The 3-year and 5-year disease-specific survival（DSS）rates were 87.09% and 78.17% respectively.There was significant difference in 5-year DSS between radiotherapy alone（RT）and RTCHEMO groups（P=0.020）.The recurrence rates was significantly different between the twogroups（P=0.004）.There was no significant difference in toxicity between RT alone and RTCHEMO（P=0.638）.Conclusion Adjuvant RTCHEMO could increase DSS and reduce the relapse rates in high-risk endometrial cancer compared to adjuvant RT alone.Postsurgical chemotherapy followed by radiation is safer and more feasible.

关 键 词：子宫内膜癌 辅助治疗 放疗 化疗 

分 类 号：R737.33[医药卫生—肿瘤]